References
- Ahn JY, Ann HW, Jeon Y, Ahn MY, Oh DH, Kim YC, Kim EJ, Song JE, Jung IY, Kim MH, et al. 2017. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea. BMC Infect Dis. 17:327.
- Armbruster CE, Mobley HLY. 2012. Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol. 10(11):743–754.
- CLSI. 2009. Performance Standards for Antimicrobial Disk Susceptibility Tests. 11th ed. CLSI standard M02. Wayne (USA): Clinical and Laboratory Standards Institute.
- Di Domenico EG, Farulla I, Prignano G, Gallo MT, Vespaziani M, Cavallo I, Sperduti I, Pontone M, Bordignon V, Cilli L, et al. 2017. Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype. Internat J Mol Sci, 18(5):1077.
- Di Pilato V, Chiarelli A, Boinett CJ, Riccobono E, Harris SR, D’Andrea M, Thomson NR, Rossolini GM, Giani T. 2016. Complete genome sequence of the first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream infection. Genome Announc. 4(3):e00607–16.
- Drzewiecka D. 2016. Significance and roles of Proteus spp. bacteria in natural environments. Microb Ecol. 72(4):741–758.
- Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. 2005. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 49:2598–2605.
- EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0 [Internet]. London (UK): The European Committee on Antimicrobial Susceptibility Testing; [cited 2018 June 27]. Available from http://www.eucast.org/clinical_breakpoints/
- Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J. 2003. Bacteremia due to tribe Proteeae: a review of 132 cases during a decade (1991–2000). Scand J Infect Dis. 35(2):98–103.
- Kwiecińska-Piróg J, Bogiel T, Gospodarek E. 2013a. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods. J Antibiot. 66(10):593–597.
- Kwiecińska-Piróg J, Skowron K, Zniszczoł K, Gospodarek E. 2013b. The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms. Biomed Res Int. 2013:1–8.
- Laupland KB, Church DL. 2014. Populations-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 27:647–664.
- Laupland KB, Parkins MD, Ross T, Pitout JDD. 2007. Population-based laboratory surveillance for tribe Proteeae isolates in a large Canadian health region. Clin Microbiol Infect. 13(7):683–688.
- Lebeaux D, Ghigo JM, Beloin C. 2014. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 78(3):510–543.
- O’Hara CM, Brenner FW, Miller JM. 2000. Classification, identification and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 13(4):534–546.
- Różalski A, Kwil I, Torzewska A, Baranowska M, Stączek P. 2007. Proteus bacilli: features and virulence factors. Post Hig Med Dosw. 61:204–219.
- Sabbuba NA, Mahenthiralingam E, Stickler DJ. 2003. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol. 41(11):4961–4965.
- Sohn KM, Kang ChI, Joo EJ, Ha YE, Chung DR, Peck KR, Lee NY, Song JH. 2011. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Proteus mirabilis bacteriemia. Korean J Intern Med. 26:89–93.
- Tumbarello M, Trecarichi EM, Fiori B, Losito AR, D’Inzeo T, Campana L, Ruggeri A, Di Meco E, Liberto E, Fadda G, et al. 2012. Multidrug-Resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 56(6):3224–3231.
- Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, Huang IW, Tan MC, Lauderdale TL. 2014. TSAR Hospitals. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC Infec Dis. 14(1):486.
- Watanakunakorn C, Perni SC. 1994. Proteus mirabilis bacteremia: a review of 176 cases during 1980–1992. Scand J Infect Dis. 26:361–367.